Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of buccal midazolam (MHOS/SHP615) in pediatric convulsive status epilepticus in community settings
jRCT2080224694Phase 3Completed
- Sponsor
- Takeda
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of midazolam in status epilepticus (SE), sponsored by Takeda. Primary endpoint: Effectiveness and tolerability of buccal MHOS/SHP615. Started May 2019; status: completed.
02
Drugs
midazolam
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on jRCT2080224694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224694.